US-based startup Bambusa Therapeutics has secured $90m in Series A financing to advance its pipeline of bispecific antibodies for immunological and inflammatory disorders into the clinic. The funding ...
Bambusa multiplex (Lour.) Raeusch. ex Schult. & Schult. f. National Museum of Natural History ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results